Director, US Market Access - New Products & Launch Planning
Kite Pharma
Summary
The Director, New Products & Launch Planning reports to the Sr Director, Head of US Payer, Value, and Access Strategy and is a portfolio-level individual contributor responsible for representing US Market Access in new product planning, pipeline strategy, and launch readiness for Kite's future cell therapy assets. This role is accountable for ensuring US access considerations are incorporated early and effectively into global planning, evidence generation, launch strategy, commercialization assumptions, and cross-functional decision making.
Job description
Key Responsibilities
New Product Planning and Pipeline Strategy
- Serve as the US Market Access lead for pipeline assets and new product planning activities
- Represent US Market Access in global and cross-functional planning forums related to pipeline assets, new indications, lifecycle opportunities, and future launch priorities
- Develop integrated US access strategies for pipeline assets, including payer, provider, reimbursement, evidence, employer, policy, and market readiness considerations
- Identify potential access risks and opportunities early in development and recommend mitigation strategies
- Ensure US Market Access perspectives are incorporated into global development plans, commercialization assumptions, evidence plans, value strategy, product positioning, and launch planning
Launch Access Strategy and Readiness
- Lead Market Access launch planning for future assets and indications, ensuring cross-functional alignment across all US Market Access functions
- Develop and maintain launch access workplans, milestones, readiness scorecards, and executive updates
- Partner with Provider Access Marketing and Payer & Value Marketing to identify required launch resources, customer tools, value materials, and stakeholder education needs
- Partner with Pricing & Contracting and Trade to ensure launch access planning reflects expected pricing, contracting, distribution, reimbursement, and operational requirements
- Ensure launch readiness plans address the first 30, 60, 90, and 180 days post-approval, including payer coverage, provider readiness, field enablement, customer resources, and access operations
Global and Cross-functional Interface
- Serve as a primary US Market Access interface to Global Market Access and applicable global asset teams
- Provide US access input into global launch planning, market research, evidence generation, payer research, value proposition development, and commercialization strategy
- Partner with Global and US teams to ensure launch assumptions are realistic and grounded in US payer, provider, employer, reimbursement, and access dynamics
- Influence cross-functional teams to prioritize access-related activities that are critical to launch success
- Ensure US Market Access leadership is informed of key pipeline decisions, launch tradeoffs, risks, and resource needs
Evidence, Value, and Guideline Planning
- Partner with HEOR, Medical Affairs, Regulatory, Global Market Access, and Payer & Value Marketing to identify payer and provider evidence needs for pipeline assets
- Identify evidence gaps that could limit coverage, reimbursement, guideline inclusion, provider adoption, or stakeholder confidence at launch
- Support development of payer evidence requirements, value narrative considerations, and launch-related evidence translation priorities
- Partner with relevant internal teams to ensure Market Access perspectives are incorporated into NCCN and guideline planning discussions where appropriate
- Ensure launch planning reflects the expected evidence package, competitive profile, indication, patient population, and access-relevant clinical considerations
Strategic Planning, Governance, and Communication
- Develop integrated launch access blueprints for pipeline assets and launch opportunities
- Establish governance routines and cross-functional workstreams to ensure Market Access launch readiness
- Partner with Portfolio & Strategic Planning to ensure new product and launch priorities are incorporated into broader US Market Access planning
- Provide clear, decision-oriented updates to US Market Access Leadership and cross-functional senior leaders
- Create executive-level materials that communicate launch risks, access assumptions, resource needs, and recommended actions
Requirements
- Advanced scientific degree (MD, PharmD, or PhD) and 8+ years of experience OR Master's Degree and 10+ years of experience OR Bachelor's Degree and 12+ years of experience
- 10+ years of relevant pharmaceutical or biotechnology experience in market access, launch planning, new product planning, payer strategy, global market access, commercial strategy, HEOR, or related roles
- Demonstrated experience supporting launch planning or new product planning for specialty, oncology, hematology, or cell therapy products
- Strong understanding of US market access, payer coverage, provider economics, reimbursement, guideline dynamics, evidence requirements, and buy-and-bill access considerations
- Experience working with global teams and influencing development, evidence, market research, and commercialization planning
- Demonstrated ability to lead complex cross-functional workstreams without direct authority
- Strong strategic thinking, analytical skills, and ability to identify access risks early and translate them into practical mitigation plans
- Experience developing launch readiness plans, launch workstreams, executive updates, and governance processes
- Deep understanding of CAR T, hematology/oncology, or specialty therapy market dynamics preferred
- Demonstrated high levels of emotional intelligence, situational awareness, and ability to collaborate effectively across functions and senior leaders
- Strong project management skills with ability to manage multiple assets, deadlines, and stakeholders
- Advanced PowerPoint and Excel skills
- Excellent verbal and written communication skills
Benefits
- Medical, Dental & Vision
- Life Insurance
- Discretionary Annual Bonus
- Stock-Based Long-Term Incentives
- Paid Time Off
Company overview
Kite Pharma, Inc. is an American biotechnology company specializing in cancer immunotherapy with a primary focus on genetically engineered autologous CAR T cell therapy. Founded in 2009 and headquartered in Santa Monica, California, Kite was acquired by Gilead Sciences in 2017 for $11.9 billion. The company develops cell-based therapies that reengineer a patient's own immune cells to attack and fight cancer cells, representing a personalized approach to cancer treatment. Kite's lead product, Yescarta (axicabtagene ciloleucel), was the first CAR T therapy approved by the FDA for treating adult patients with relapsed or refractory large B-cell lymphoma. With approximately 2,000 employees and manufacturing facilities in California, Maryland, and the Netherlands, Kite operates as an independent company within Gilead Sciences while maintaining its singular focus on advancing cell therapy to treat and potentially cure cancer. The company's innovative approach represents a paradigm shift in cancer treatment, moving away from traditional pharmaceutical manufacturing to individualized cell therapies created one patient at a time.